New 52-week results from Lilly's TOGETHER-PsA Phase 3b open-label trial showed that Taltz (ixekizumab) and Zepbound (tirzepatide) used together maintained or further improved outcomes across disease activity, patient-reported and metabolic measures through one year in adults with active psoriatic arthritis and obesity or overweight with at least one additional weight-related comorbid condition. The findings were presented at ACR Convergence 2026 and published in Arthritis & Rheumatology.
At one year, nearly three times as many patients taking Taltz and Zepbound achieved ACR50, reflecting at least a 50% reduction in PsA disease activity, compared with Taltz alone: 43.7% versus 15.7%. A greater proportion achieving ACR50 was seen in the combination arm as early as Week 4, before clinically meaningful weight loss was observed. On the primary endpoint of ACR50 plus at least 10% weight reduction, 39.2% achieved both at Week 52 versus 1.7% for Taltz alone, and 85.7% of combination-arm patients achieved at least 10% weight reduction versus 6.7%.
Patient-reported outcomes including physical function and fatigue were maintained or further improved from Week 36 to Week 52 versus Taltz alone. The combination was also associated with improvements in BMI, body weight, systolic blood pressure, glucose, HbA1c, triglycerides and total cholesterol versus Taltz monotherapy.
TOGETHER-PsA randomized 271 participants 1:1 to Taltz alone or with Zepbound, both administered subcutaneously, with all patients receiving diet and exercise counseling. Patients had a mean baseline BMI of 37.6. Adverse events with the combination were generally mild to moderate and consistent with the known safety profiles of each medicine. Week 52 analyses were exploratory objectives without multiplicity control.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!